MDM2 inhibition induces apoptosis in primitive CD34+ proliferating and quiescent CML cells from BC CML patients and sensitizes to ABT-737 and nilotinib. Here, CD34 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.